Browse by author
Lookup NU author(s): Dr James Roberts
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
This paper reviews the current status of systemic chemotherapy in the management of advanced and metastatic urothelial cancer. The activity of a number of single agents and combination drug regimens is discussed, and the small, number of randomised-controlled. studies available is also considered. Prognostic factors for response and survival, particularly long-term. survival after. systemic chemotherapy, are also reviewed. Special consideration is given to the role of systemic chemotherapy as a precursor to surgery (or radiotherapy) in locally advanced disease that is initially considered incurable. Therapeutic options for patients unable to tolerate cisplatin owing to renal impairment or other comorbidities are explored. Future directions Are explored, including the role of molecular phenotyping in providing prognostic information, indicators of the likely success of conventional therapeutic measures and the development of specific targeted therapies.
Author(s): Roberts JT
Publication type: Article
Publication status: Published
Journal: Clinical Oncology
Year: 2005
Volume: 17
Issue: 7
Pages: 514-523
ISSN (print): 0936-6555
ISSN (electronic): 1433-2981
Publisher: WB Saunders Co. Ltd.
URL: http://dx.doi.org/10.1016/j.clon.2005.07.007
DOI: 10.1016/j.clon.2005.07.007
Altmetrics provided by Altmetric
